IMG-20260527-WA0000.jpg

Answer them

Reading File

Now I'll run parallel searches for all 5 questions simultaneously.Searching sources...

Finding Sources

Reading File

Finding Sources

Reading File

Now I have enough from the library. Let me read further content on antimalarials and the septic shock management section, and also get details on the Anaemia Mukt Bharat programme targets and beneficiaries.

Reading File

Finding Sources

I now have sufficient information from the library. Let me compile comprehensive answers for all questions.---

FORMATIVE ASSESSMENT 2 - ANSWERS

ESSAY (15 Marks)

Question 1

Clinical Summary: 2-year-old girl, fever 6 days, vomiting + lethargy 1 day, cool peripheries 2 hours, reduced urine output. On examination: HR 154/min, RR 44/min, BP 90/80 mmHg, CRT >3 sec, SpO2 93%, afebrile, right hypochondrial tenderness, liver span 8 cm, reduced air entry over right infraaxillary, interscapular, and infrascapular areas.

DIAGNOSIS

Primary diagnosis: Septic Shock (Cold Shock) secondary to Pneumonia with Right-sided Parapneumonic Pleural Effusion/Empyema

Fever 6 days + tachycardia (HR 154) + tachypnoea (RR 44) + SpO2 93% = sepsis with respiratory focus
Cool peripheries + CRT >3 sec + reduced urine output + hypotension (BP 90/80, which is low-normal for 2 years) = signs of reduced perfusion / cold shock
Reduced air entry right infraaxillary + interscapular + infrascapular = right lower lobe pneumonia with pleural effusion
Right hypochondrial tenderness + hepatomegaly (liver span 8 cm at 2 years is enlarged) = hepatic congestion from sepsis or possible hepatic abscess as a complication

AETIOLOGY

The most likely organisms causing community-acquired pneumonia/empyema in a 2-year-old:

Organism	Notes
Streptococcus pneumoniae	Most common cause of parapneumonic empyema in children
Staphylococcus aureus	Second most common; produces necrotizing pneumonia and empyema rapidly
Streptococcus pyogenes (Group A Strep)	Can cause large effusions
Haemophilus influenzae type b	Less common post-vaccination
Klebsiella pneumoniae	Gram-negative; consider if hospital exposure
Respiratory viruses (RSV, influenza)	Can predispose to secondary bacterial pneumonia

Predisposing factors for septic shock in children include: young age (<1 month is highest risk, but 2 years is still vulnerable), malnutrition, lack of vaccination, and immune dysfunction.

CLASSIFICATION

Classification of Septic Shock (Paediatric):

By haemodynamic pattern:

Cold (Hypodynamic) Shock - low CO, high SVR: cool extremities, prolonged CRT, thready pulse - This child has cold shock
Warm (Hyperdynamic) Shock - high CO, low SVR: warm extremities, bounding pulse, flash CRT

Severity (Surviving Sepsis Campaign - Paediatric):

Sepsis - infection + SIRS criteria (2 of: abnormal temperature, tachycardia/bradycardia, tachypnoea, abnormal WBC count)
Severe Sepsis - sepsis + organ dysfunction (respiratory, cardiovascular, renal, CNS, hepatic)
Septic Shock - severe sepsis + hypotension refractory to ≥40 mL/kg IV fluid in 1 hour, OR vasopressor requirement - This child is here

Classification of Pleural Effusion (Light's criteria adapted for paediatric empyema - AETS staging):

Stage 1: Exudative (free-flowing)
Stage 2: Fibrinopurulent (loculated)
Stage 3: Organizing (thick fibrous peel)

INVESTIGATIONS

Immediate (Bedside):

Capillary blood glucose (hypoglycaemia in sepsis)
Arterial/venous blood gas: metabolic acidosis, lactate (>4 mmol/L = 3.3x increased 30-day mortality)
Pulse oximetry (already SpO2 93%)

Blood:

CBC with differential: leukocytosis or leukopenia
CRP, ESR, Procalcitonin (sepsis markers)
Blood culture (2 sets before antibiotics - MUST NOT delay antibiotics for this)
Serum electrolytes, urea, creatinine (organ function)
LFTs (hepatomegaly noted - assess hepatic dysfunction)
Coagulation profile (PT, aPTT, fibrinogen) - screen for DIC
Serum albumin, total protein

Urine:

Urinalysis + urine culture

Radiology:

Chest X-ray (AP + lateral): Confirm right-sided pneumonia + pleural effusion; assess volume
Ultrasound chest: Characterise effusion - free-flowing vs loculated, guides diagnostic tap
Chest CT (if indicated): To identify empyema vs abscess, guide thoracic intervention

Pleural Fluid Analysis (if tapped):

Appearance (pus = empyema), pH, glucose, protein, LDH, cell count, Gram stain, culture and sensitivity, ADA

Microbiology:

Throat swab, NP swab (viral PCR panel)
Malaria smear (given fever pattern and hepatomegaly in endemic region)

MANAGEMENT

1. Immediate Resuscitation (ABC)

Airway: Ensure patent; high-flow O2 via non-rebreather mask to target SpO2 ≥94%
IV Access: Two large-bore IVs or intraosseous if IV access fails
Fluid Resuscitation:
- Bolus: 10-20 mL/kg isotonic saline (0.9% NS) over 5-10 minutes
- Reassess after each bolus for HR, CRT, urine output, BP, lung aeration
- Up to 40-60 mL/kg in first hour per 2020 Surviving Sepsis Campaign guidelines
- Stop/slow if crackles, worsening SpO2, or hepatomegaly worsens (fluid overload risk)

2. Antibiotics (within 1 hour of recognition)

Give broad-spectrum antibiotics immediately; do not delay for culture results:

Ceftriaxone 80-100 mg/kg/day IV (community-acquired pneumonia, covers S. pneumoniae)
Add Cloxacillin/Clindamycin if Staphylococcal empyema suspected (necrotic changes, rapid progression)
Tailor to culture and sensitivity results when available

3. Vasopressors (if fluid-refractory shock)

If no improvement after 40-60 mL/kg fluid:

Dopamine (first-line in cold shock): 5-20 mcg/kg/min
Norepinephrine (if warm/vasodilated shock) OR Epinephrine (cold shock, fluid-refractory): 0.05-0.3 mcg/kg/min
Consider hydrocortisone if vasopressor-refractory and suspected adrenal insufficiency

4. Pleural Effusion/Empyema Management

Ultrasound-guided diagnostic thoracocentesis to characterise fluid
If exudative parapneumonic effusion: IV antibiotics usually sufficient
If empyema (pus, low pH <7.2, high LDH, loculations): Intercostal chest drain (ICD) insertion
Intrapleural fibrinolytics (urokinase/streptokinase) for loculated empyema (Stage 2)
Video-assisted thoracoscopic surgery (VATS) or open decortication for Stage 3 organizing empyema

5. Monitoring and Supportive Care

Strict input/output monitoring (target urine output >1 mL/kg/hour)
Continuous cardiac and SpO2 monitoring
Manage fever (paracetamol 15 mg/kg)
Nutritional support (NG feeding once stable)
ICU admission given septic shock

6. Specific Investigations Treatment Targets

Parameter	Target
HR	Age-appropriate normal
CRT	<2 seconds
BP	MAP ≥5th percentile for age
SpO2	≥94%
Urine output	≥1 mL/kg/hour
Lactate	Clearance ≥10% per hour

SHORT ANSWERS (4 x 5 = 20 Marks)

Short Answer 1: Anaemia Mukt Bharat Programme

Anaemia Mukt Bharat (AMB) is a national strategy launched by the Government of India as part of POSHAN Abhiyaan (National Nutrition Mission) to reduce the prevalence of anaemia in India by 3 percentage points per year over 5 years (target: from ~50% to ~35% in children 6-59 months).

Target Beneficiaries (6 age groups):

Children 6-59 months
Children 5-9 years
Adolescent girls and boys 10-19 years (WIFS - Weekly Iron and Folic Acid Supplementation)
Pregnant women
Lactating women
Women of reproductive age (15-49 years)

Six Core Interventions:

Prophylactic Iron and Folic Acid (IFA) supplementation - age-specific IFA doses delivered through ASHA, anganwadis, schools
Deworming - biannual deworming with Albendazole 400 mg (National Deworming Day - 10 Feb and 10 Aug)
Behaviour Change Communication (BCC) - "Solid Body, Smart Mind" campaign focusing on:
- Compliance with IFA and deworming
- Appropriate IYCF (infant and young child feeding) practices
- Diet diversity - iron-rich foods, locally available resources
- Delayed cord clamping (at least 3 minutes after delivery in health facilities)
Testing and Treatment - digital point-of-care haemoglobin testing (e.g., HemoCue), especially for pregnant women and school children; treat with therapeutic IFA doses
Mandatory provision of IFA-fortified foods in government-funded programmes (ICDS, mid-day meal, PDS)
Non-nutritional anaemia screening and treatment - especially malaria, haemoglobinopathies, and fluorosis in endemic areas

Delivery Platforms: NIPI (National Iron Plus Initiative) + WIFS programme, delivered through ANMs, ASHAs, anganwadi workers, school health teams.

Park's Textbook of Preventive and Social Medicine, p. 756

Short Answer 2: Newer Anti-Malarial Drugs

The newer antimalarials can be grouped based on their mechanism and origin:

A. Artemisinins (Most Important "New" Class)

Derived from Artemisia annua (sweet wormwood). Mechanism: Free radical generation from cleavage of endoperoxide bridge by heme iron in the parasite's food vacuole - kills intraerythrocytic forms rapidly.

Members:

Drug	Route	Notes
Artesunate	IV/IM/oral/rectal	Preferred for severe falciparum malaria; FDA-approved for IV use
Artemether	IM/oral	Used in ACT (artemether-lumefantrine = Coartem)
Dihydroartemisinin (DHA)	Oral	Active metabolite; used in DHA-piperaquine combination
Artemisinin	Oral	Parent compound; largely replaced by derivatives

Artemisinin-Based Combination Therapies (ACTs) - WHO first-line for uncomplicated falciparum malaria:

Artemether + Lumefantrine (Coartem): Only ACT FDA-approved in the USA; no clear resistance to lumefantrine documented
Artesunate + Amodiaquine
Artesunate + Mefloquine: Effective for multidrug-resistant falciparum in Southeast Asia
Artesunate + Pyronaridine: Newer ACT; no resistance to pyronaridine reported
Dihydroartemisinin + Piperaquine (DHA-PQP)

Note: ACTs combine a rapidly-acting artemisinin derivative with a longer-acting partner drug to prevent recrudescence and reduce resistance emergence.

B. Atovaquone-Proguanil (Malarone)

Atovaquone: Hydroxynaphthoquinone; inhibits mitochondrial electron transport chain, ATP synthesis, and pyrimidine biosynthesis
Proguanil (via cycloguanil metabolite): Inhibits plasmodial dihydrofolate reductase - prevents DNA synthesis (metabolised by CYP2C19)
Used for: prophylaxis and treatment of chloroquine-resistant P. falciparum; travelers from non-endemic areas
Not for routine use in endemic areas due to high risk of resistance development
Take with food/milk to enhance absorption

C. Tafenoquine

A long-acting 8-aminoquinoline (analogue of primaquine)
Single-dose treatment for P. vivax radical cure (prevents relapse from liver hypnozoites)
FDA-approved (2018); advantage over primaquine: single dose vs 14-day course
Contraindicated in G6PD deficiency (causes haemolysis)

D. Mefloquine

4-methanolquinoline related to quinine
Long half-life (~20 days); used for prophylaxis and treatment of multidrug-resistant P. falciparum (in combination with artemisinin derivative)
Risk of neuropsychiatric adverse effects (hallucinations, depression, anxiety) limits use

E. Pyronaridine

Mannich base antimalarial; used in artesunate-pyronaridine ACT (Pyramax)
Effective against both P. falciparum and P. vivax
No documented resistance

Sources: Lippincott Illustrated Reviews Pharmacology; Goodman & Gilman's Pharmacological Basis of Therapeutics; Goldman-Cecil Medicine

Short Answer 3: 15-Month-Old with Irritability, Vomiting, Delayed Motor Milestones, HC 50 cm

Probable Diagnosis: Hydrocephalus

Justification:

HC 50 cm at 15 months is above the 98th percentile (normal HC at 15 months ~46-47 cm); this represents macrocephaly
Delayed motor milestones: has NOT started standing with support (expected by 9-10 months) - suggests chronic raised ICP affecting corticospinal tracts
Irritability and vomiting: classic signs of raised ICP in infancy - irritability is a common presenting symptom, and vomiting (often worse in morning) results from increased ICP
In children <2 years, skull sutures are still open, so increasing ICP causes head circumference to enlarge rather than produce papilloedema - the large head IS the sign

"In children younger than 2 years of age, enlargement of the ventricles produces an increase in head circumference because the skull sutures are still open... During the neonatal and early childhood period, irritability is a common symptom of hydrocephalus. The child feeds poorly, appears fretful, and may be lethargic... Acute enlargement of the ventricles is associated with nausea and vomiting." - Bradley and Daroff's Neurology in Clinical Practice

Aetiologies of Hydrocephalus in Children:

Obstructive (Non-communicating):

Aqueductal stenosis (most common - congenital or post-infectious)
Chiari malformation (Type I or II with Arnold-Chiari)
Dandy-Walker malformation (posterior fossa cyst + absent/hypoplastic cerebellar vermis)
Brain tumours (e.g., medulloblastoma, ependymoma obstructing 4th ventricle)
Vein of Galen malformation

Communicating (Non-obstructive):

Post-meningitis (scarring of arachnoid granulations) - very common
Post-intraventricular haemorrhage (in preterm infants)
Congenital infections (TORCH - toxoplasma, CMV)
Choroid plexus papilloma (excess CSF production)

Differential Diagnosis:

Diagnosis	Distinguishing Features
Hydrocephalus	Macrocephaly + raised ICP signs + motor delay
Megalencephaly (true large brain)	No raised ICP signs, often familial
Subdural haematoma/hygroma	History of trauma; neuroimaging distinguishes
Rickets (frontal bossing)	Soft bones, widened fontanelle, no motor delay from ICP
Autism/global developmental delay	No macrocephaly, no raised ICP
Storage disorders (e.g., Hurler)	Coarse facies, organomegaly, skeletal changes
Cerebral tumour	Focal neurological signs, no skull suture separation

Investigations:

Neuroimaging:
- Cranial Ultrasound (1st line if anterior fontanelle open): non-invasive, no sedation needed, can visualise dilated ventricles
- MRI Brain (gold standard): identifies cause (aqueductal stenosis, Chiari, tumour, scarring), characterises ventricular morphology
- CT Brain (if MRI unavailable or urgent): dilated ventricles, transependymal flow (periventricular lucency)
Head circumference plot on WHO growth chart (serial measurements)
Fundoscopy: Papilloedema (may be absent at this age)
TORCH screen (if congenital cause suspected): CMV, toxoplasma, rubella serology
CSF analysis (if meningitis history): after imaging rules out obstructive cause
Karyotype if dysmorphic features suggest chromosomal syndrome

Management:

Medical (temporising):

Acetazolamide (carbonic anhydrase inhibitor - reduces CSF production): used short-term
Furosemide (adjunct)
Elevated head positioning, seizure management

Surgical (definitive):

Ventriculoperitoneal (VP) shunt - gold standard; CSF diverted to peritoneal cavity; complications include infection, malfunction, over-drainage
Endoscopic Third Ventriculostomy (ETV) - preferred for obstructive hydrocephalus (aqueductal stenosis); creates a bypass in the floor of 3rd ventricle; avoids shunt hardware
ETV + Choroid Plexus Cauterization (ETV+CPC) - for infants in resource-limited settings; reduces CSF production
Treat underlying cause: e.g., surgical resection of posterior fossa tumour, medical treatment of meningitis

Monitoring post-surgery: Serial HC measurements, developmental assessment, neuroimaging to confirm adequate decompression.

Short Answer 4: 3-Day-Old Baby with Flat Face, Flat Occiput, Upward Slanting Eyes, Open Mouth, Hypotonia, Abnormal Palmar and Plantar Creases

Diagnosis: Down Syndrome (Trisomy 21)

Justification of Features:

Flat facial profile - characteristic dysmorphic feature
Flat occiput (brachycephaly)
Upward-slanting palpebral fissures with epicanthic folds
Open mouth with protruding tongue
Hypotonia - generalized hypotonia is universal in Down syndrome ("floppy baby")
Abnormal palmar crease - single transverse palmar crease (Simian crease) in ~50%
Abnormal plantar creases - wide gap between 1st and 2nd toes (sandal gap)

"The diagnostic clinical features of this condition - flat facial profile, oblique palpebral fissures, and epicanthic folds - are usually apparent at birth." - Robbins & Kumar Basic Pathology

Associated Co-morbidities to Screen For:

System	Co-morbidity	Screening
Cardiovascular	Congenital heart disease in ~40% (commonest: AVSD - endocardial cushion defect; also ASD, VSD)	Echocardiogram within 1st month
GI	Duodenal atresia ("double-bubble" on X-ray), Hirschsprung disease, oesophageal atresia, imperforate anus	Abdominal X-ray, clinical assessment for feeding intolerance
Haematology	Transient abnormal myelopoiesis (TAM) in neonates; 10-20x increased risk of AML and ALL later	CBC with differential; blood film
Thyroid	Congenital hypothyroidism (more frequent than general population)	TSH, T4 on neonatal screening
Hearing	Sensorineural and conductive hearing loss	Newborn hearing screening (OAE)
Vision	Cataracts (screen at birth), refractive errors, nystagmus, strabismus	Red reflex examination within 24 hours
Neurology	Atlantoaxial instability (C1-C2 instability - risk of cord compression)	Cervical spine X-ray at ~3 years; screen before contact sports
Respiratory	Recurrent pulmonary infections (due to immune dysfunction - mainly T-cell abnormalities), obstructive sleep apnoea	Sleep study in childhood
Immunology	Increased risk of serious infections	Monitor; ensure full vaccination
CNS (long-term)	Alzheimer's disease (virtually all >40 years develop neuropathological changes)	Long-term follow-up

How to Confirm the Diagnosis:

Gold Standard: Chromosomal Karyotype

Conventional karyotype (G-banding): Takes 2-3 weeks; gold standard; identifies:
- Trisomy 21 (free trisomy) - 95% of cases: 47,XX,+21 or 47,XY,+21
- Translocation Down syndrome - ~4%: extra chromosome 21 material translocated onto chromosome 14 or 22 (important for recurrence risk counselling)
- Mosaic Down syndrome - ~1%: mixture of 46 and 47 chromosome cells

Rapid/Preliminary Tests:

Fluorescence In Situ Hybridisation (FISH): Uses chromosome 21-specific fluorescent probe; result in 24-48 hours; does NOT distinguish free trisomy from translocation
Chromosomal Microarray (CMA/SNP array): Faster, higher resolution; can detect submicroscopic imbalances; useful if karyotype inconclusive
QF-PCR (Quantitative Fluorescence PCR): Rapid (48 hours); detects dosage of chromosome 21 markers

Parental Karyotype: Mandatory if translocation is identified on the baby's karyotype, to assess recurrence risk (carrier parent = up to 10-15% recurrence risk vs <1% for free trisomy).

Genetic Counselling should be offered to all parents of confirmed Down syndrome children.

Sources: Robbins & Kumar Basic Pathology; Goldman-Cecil Medicine; Bradley and Daroff's Neurology in Clinical Practice; Lippincott Illustrated Reviews Pharmacology; Goodman & Gilman's Pharmacological Basis of Therapeutics; Park's Textbook of Preventive and Social Medicine; Rosen's Emergency MedicineAll five questions have been answered in full. Here is a quick summary of what was covered:

Essay Q1 (15 marks): The 2-year-old has Septic Shock (cold type) secondary to right-sided bacterial pneumonia with parapneumonic pleural effusion/empyema. The key indicators are fever + tachycardia/tachypnoea + cool peripheries + CRT >3 sec + reduced urine output + unilateral reduced air entry. The answer covers organisms (S. pneumoniae, S. aureus being most likely), the SIRS-to-septic-shock classification, stepwise investigations (VBG, lactate, blood cultures, CXR, US chest, pleural tap), and management (ABC resuscitation, fluid boluses up to 60 mL/kg, Ceftriaxone ± Cloxacillin, vasopressors if fluid-refractory, ICD for empyema, PICU).

Short Q1 - Anaemia Mukt Bharat: A universal national strategy targeting 6 beneficiary groups with 6 core interventions - IFA supplementation, deworming, BCC campaign, point-of-care testing and treatment, IFA-fortified foods, and non-nutritional anaemia management.

Short Q2 - Newer Antimalarials: Artemisinins (artesunate, artemether, DHA) and their ACT combinations (Coartem, DHA-piperaquine, artesunate-pyronaridine), atovaquone-proguanil (Malarone), tafenoquine (single-dose radical cure for P. vivax), and mefloquine - with mechanisms, indications, and key adverse effects.

Short Q3 - 15-month-old: Diagnosis is Hydrocephalus (HC 50 cm = macrocephaly, delayed motor milestones, irritability, vomiting from raised ICP). Covers aetiology (aqueductal stenosis, post-meningitis, Chiari, Dandy-Walker, tumour), differential diagnoses, investigations (cranial ultrasound + MRI), and management (VP shunt vs ETV).

Short Q4 - 3-day-old: Diagnosis is Down Syndrome (Trisomy 21). Screens for CHD (ECHO), duodenal atresia, TAM/leukaemia, hypothyroidism, hearing loss, cataracts, and atlantoaxial instability. Confirmed by chromosomal karyotype (gold standard) or rapid FISH/QF-PCR; parental karyotype essential if translocation found.

This is a shared conversation. Sign in to Orris to start your own chat.